Background
Methods
Data sources
Subtype | ICD-10 |
---|---|
Hodgkin lymphoma | C81 |
Nodular lymphocyte predominant Hodgkin lymphoma | C81.0 |
Nodular sclerosis (classical) Hodgkin lymphoma | C81.1 |
Mixed cellularity (classical) Hodgkin lymphoma | C81.2 |
Lymphocyte-depleted (classical) Hodgkin lymphoma | C81.3 |
Lymphocyte-rich (classical) Hodgkin lymphoma | C81.4 |
Other (classical) Hodgkin lymphoma | C81.7 |
Hodgkin lymphoma, unspecified | C81.9 |
Follicular lymphoma | C82 |
Follicular lymphoma grade I | C82.0 |
Follicular lymphoma grade II | C82.1 |
Follicular lymphoma grade III, unspecified | C82.2 |
Follicular lymphoma grade IIIa | C82.3 |
Follicular lymphoma grade IIIb | C82.4 |
Diffuse follicle center lymphoma | C82.5 |
Cutaneous follicle center lymphoma | C82.6 |
Other types of follicular lymphoma | C82.7 |
Follicular lymphoma, unspecified | C82.9 |
Non-follicular lymphoma | C83 |
Small cell B cell lymphoma | C83.0 |
Mantle cell lymphoma | C83.1 |
Diffuse large B cell lymphoma | C83.3 |
Lymphoblastic (diffuse) lymphoma | C83.5 |
Burkitt lymphoma | C83.7 |
Other non-follicular lymphoma | C83.8 |
Non-follicular (diffuse) lymphoma, unspecified | C83.9 |
Mature T/NK cell lymphomas | C84 |
Mycosis fungoides | C84.0 |
Sézary disease | C84.1 |
Peripheral T cell lymphoma, not elsewhere classified | C84.4 |
Other mature T/NK cell lymphomas | C84.5 |
Anaplastic large cell lymphoma, ALK-positive | C84.6 |
Anaplastic large cell lymphoma, ALK-negative | C84.7 |
Cutaneous T cell lymphoma, unspecified | C84.8 |
Mature T/NK cell lymphoma, unspecified | C84.9 |
Other and unspecified types of non-Hodgkin lymphoma | C85 |
B cell lymphoma, unspecified | C85.1 |
Mediastinal (thymic) large B cell lymphoma | C85.2 |
Other specified types of non-Hodgkin lymphoma | C85.7 |
Non-Hodgkin lymphoma, unspecified | C85.9 |
Other specified types of T/NK cell lymphoma | C86 |
Extranodal NK/T cell lymphoma, nasal type | C86.0 |
Hepatosplenic T cell lymphoma | C86.1 |
Enteropathy-type (intestinal) T cell lymphoma | C86.2 |
Subcutaneous panniculitis-like T cell lymphoma | C86.3 |
Blastic NK cell lymphoma | C86.4 |
Angioimmunoblastic T cell lymphoma | C86.5 |
Primary cutaneous CD30-positive T cell proliferations | C86.6 |
Malignant immunoproliferative diseases | C88 |
Waldenström macroglobulinemia | C88.0 |
Other heavy chain diseases | C88.2 |
Immunoproliferative small intestinal disease | C88.3 |
Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue [MALT lymphoma] | C88.4 |
Other malignant immunoproliferative diseases | C88.7 |
Malignant immunoproliferative disease, unspecified | C88.9 |
Multiple myeloma and malignant plasma cell neoplasms | C90 |
Multiple myeloma | C90.0 |
Plasma cell leukemia | C90.1 |
Extramedullary plasmacytoma | C90.2 |
Solitary plasmacytoma | C90.3 |
Other and unspecified malignant neoplasms of lymphoid, hematopoietic, and related tissue | C96 |
Multifocal and multisystemic (disseminated) Langerhans cell histiocytosis [Letterer-Siwe disease] | C96.0 |
Malignant mast cell tumor | C96.2 |
Sarcoma of dendritic cells (accessory cells) | C96.4 |
Multifocal and unisystemic Langerhans cell histiocytosis | C96.5 |
Unifocal Langerhans cell histiocytosis | C96.6 |
Other specified malignant neoplasms of lymphoid, hematopoietic, and related tissue | C96.7 |
Histiocytic sarcoma | C96.8 |
Malignant neoplasm of lymphoid, hematopoietic, and related tissue, unspecified | C96.9 |
Statistical analysis
Results
Expected deaths and mortality rates of lymphoma and myeloma in 2017
Sex | Deaths (× 103) | Crude rate (1/105) | ASMRC (1/105) | ASMRW (1/105) | |
---|---|---|---|---|---|
All | Both | 52 | 3.83 | 3.74 | 2.60 |
Male | 32 | 4.67 | 4.54 | 3.30 | |
Female | 20 | 2.97 | 2.91 | 1.93 | |
Urban | Both | 29 | 4.43 | 4.35 | 2.97 |
Male | 18 | 5.28 | 4.53 | 3.73 | |
Female | 11 | 3.57 | 2.91 | 2.25 | |
Rural | Both | 23 | 3.52 | 3.74 | 2.42 |
Male | 14 | 4.35 | 4.53 | 3.09 | |
Female | 9 | 2.66 | 2.91 | 1.77 |
Age-specific mortality rates of lymphoma and myeloma stratified by residence and sex
Age group | All areas | Urban areas | Rural areas | ||||||
---|---|---|---|---|---|---|---|---|---|
Both | Male | Female | Both | Male | Female | Both | Male | Female | |
0–1 | 0.34 | 0.56 | 0.08 | 0.00 | 0.00 | 0.00 | 0.46 | 0.74 | 0.11 |
1–4 | 0.26 | 0.30 | 0.20 | 0.17 | 0.19 | 0.15 | 0.29 | 0.3 | 0.22 |
5–9 | 0.33 | 0.41 | 0.24 | 0.32 | 0.40 | 0.22 | 0.34 | 0.42 | 0.25 |
10–14 | 0.37 | 0.44 | 0.30 | 0.37 | 0.51 | 0.20 | 0.38 | 0.41 | 0.34 |
15–19 | 0.45 | 0.55 | 0.33 | 0.40 | 0.53 | 0.26 | 0.47 | 0.57 | 0.37 |
20–24 | 0.34 | 0.49 | 0.18 | 0.21 | 0.26 | 0.16 | 0.41 | 0.62 | 0.19 |
25–29 | 0.49 | 0.65 | 0.34 | 0.46 | 0.60 | 0.32 | 0.51 | 0.67 | 0.35 |
30–34 | 0.86 | 1.02 | 0.70 | 0.86 | 1.12 | 0.60 | 0.86 | 0.96 | 0.76 |
35–39 | 0.89 | 1.17 | 0.59 | 0.79 | 0.93 | 0.65 | 0.95 | 1.32 | 0.56 |
40–44 | 1.26 | 1.55 | 0.96 | 1.13 | 1.13 | 1.13 | 1.33 | 1.77 | 0.87 |
45–49 | 1.90 | 2.22 | 1.59 | 1.80 | 1.91 | 1.70 | 1.96 | 2.38 | 1.54 |
50–54 | 5.31 | 6.53 | 4.03 | 5.29 | 6.82 | 3.66 | 5.32 | 6.38 | 4.22 |
55–59 | 4.33 | 5.57 | 3.07 | 4.67 | 6.13 | 3.20 | 4.14 | 5.27 | 3.00 |
60–64 | 10.27 | 13.06 | 7.41 | 12.24 | 15.30 | 9.12 | 9.35 | 12.01 | 6.61 |
65–69 | 14.85 | 18.90 | 10.83 | 17.31 | 21.82 | 12.86 | 13.73 | 17.57 | 9.91 |
70–74 | 17.28 | 21.86 | 12.85 | 20.07 | 24.42 | 16.06 | 15.86 | 20.61 | 11.14 |
75–79 | 18.67 | 23.61 | 14.29 | 23.94 | 31.02 | 17.77 | 15.89 | 19.75 | 12.43 |
80–84 | 25.23 | 32.59 | 19.35 | 37.29 | 44.39 | 31.39 | 19.45 | 26.73 | 13.76 |
85+ | 26.69 | 37.90 | 19.70 | 43.76 | 60.33 | 32.72 | 18.64 | 26.66 | 13.81 |
Age-specific mortality rates of lymphoma and myeloma stratified by region
Age group | Eastern China | Central China | Western China | ||||||
---|---|---|---|---|---|---|---|---|---|
Both | Male | Female | Both | Male | Female | Both | Male | Female | |
0–1 | 0.30 | 0.56 | 0.00 | 0.31 | 0.57 | 0.00 | 0.43 | 0.54 | 0.31 |
1–4 | 0.20 | 0.23 | 0.17 | 0.25 | 0.36 | 0.11 | 0.35 | 0.33 | 0.38 |
5–9 | 0.32 | 0.34 | 0.29 | 0.27 | 0.33 | 0.20 | 0.43 | 0.63 | 0.23 |
10–14 | 0.31 | 0.28 | 0.34 | 0.44 | 0.60 | 0.24 | 0.38 | 0.45 | 0.31 |
15–19 | 0.32 | 0.36 | 0.28 | 0.51 | 0.67 | 0.33 | 0.53 | 0.65 | 0.40 |
20–24 | 0.27 | 0.35 | 0.17 | 0.34 | 0.47 | 0.21 | 0.45 | 0.74 | 0.16 |
25–29 | 0.49 | 0.72 | 0.26 | 0.52 | 0.67 | 0.38 | 0.46 | 0.48 | 0.44 |
30–34 | 0.84 | 0.94 | 0.73 | 0.79 | 0.93 | 0.65 | 1.00 | 1.27 | 0.72 |
35–39 | 0.97 | 1.28 | 0.65 | 0.97 | 1.35 | 0.59 | 0.68 | 0.84 | 0.52 |
40–44 | 1.27 | 1.35 | 1.19 | 1.06 | 1.39 | 0.73 | 1.52 | 2.06 | 0.95 |
45–49 | 1.81 | 1.99 | 1.63 | 1.77 | 2.05 | 1.50 | 2.23 | 2.77 | 1.68 |
50–54 | 4.64 | 5.79 | 3.43 | 5.69 | 6.98 | 4.36 | 6.08 | 7.34 | 4.74 |
55–59 | 4.87 | 6.13 | 3.59 | 4.16 | 5.55 | 2.76 | 3.61 | 4.62 | 2.60 |
60–64 | 11.56 | 14.54 | 8.54 | 9.36 | 12.14 | 6.51 | 9.33 | 11.84 | 6.72 |
65–69 | 16.78 | 21.57 | 12.12 | 14.72 | 18.99 | 10.44 | 11.87 | 14.49 | 9.23 |
70–74 | 18.94 | 24.18 | 14.00 | 15.99 | 21.21 | 10.81 | 16.24 | 18.95 | 13.59 |
75–79 | 20.16 | 25.38 | 15.69 | 18.15 | 22.14 | 14.47 | 16.53 | 22.42 | 11.21 |
80–84 | 28.52 | 36.38 | 22.69 | 23.92 | 30.54 | 18.29 | 19.95 | 27.91 | 13.17 |
85+ | 30.27 | 43.30 | 22.53 | 24.14 | 34.85 | 17.31 | 22.45 | 31.00 | 16.74 |
Trends in mortality of lymphoma and myeloma
Sex | Trend 1# | Trend 2# | Trend 3# | ||||
---|---|---|---|---|---|---|---|
Year | APC | Year | APC | Year | APC | ||
All | Both | 2004–2016 | 4.5* | ||||
Male | 2004–2016 | 4.4* | |||||
Female | 2004–2006 | − 1.2 | 2006–2016 | 5.5* | |||
Urban | Both | 2004–2016 | 2.3* | ||||
Male | 2004–2016 | 1.9* | |||||
Female | 2004–2016 | 2.9* | |||||
Rural | Both | 2004–2016 | 6.8* | ||||
Male | 2004–2016 | 6.7* | |||||
Female | 2004–2007 | − 2.3 | 2007–2016 | 9.1* |